Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European CommissionGlobeNewswire Nov 17, 2026, 2:25:00 PM
Edesa Biotech to Present at Guggenheim Healthcare Innovation ConferenceGlobeNewswire Nov 4, 2026, 9:30:00 PM
Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo StudyGlobeNewswire Oct 15, 2026, 1:15:00 PM
Edesa Biotech Announces Pricing of $25.0 Million Public OfferingGlobeNewswire Aug 20, 2026, 2:20:00 AM